白斑：市場展望、流行病學、競爭格局、市場預測報告（2026-2036年）

市場概覽

• 法國白斑市場預計將從 2026 年的 1.1 億美元成長到 2036 年的 2.75 億美元。
• 以下因素正在推動市場成長：
• 擴大標靶治療的應用，包括局部用藥和全身性治療。
• 提高對該疾病的認知和診斷水平
• 未來的成長取決於能夠實現持續色素再生和長期疾病控制的治療方法。

白癜風市場展望及預測

白癜風概述

白斑症是一種慢性自體免疫皮膚病，其特徵是出現邊界清晰的色素脫失斑塊，這是由於免疫介導的黑色素細胞破壞和功能障礙所致。白斑可能發生於皮膚的任何部位，包括毛髮、黏膜和其他含色素組織。其病程差異很大，從局部穩定期到活動期不等，部分患者會出現自發性色素恢復。除了可見的症狀外，白斑也會嚴重影響患者的生活品質，導致心理社會困擾、社會歧視和自信心下降。治療旨在透過局部應用皮質類固醇、局部應用Calcineurin抑制劑、照光治療以及對合格的患者進行手術治療來抑制疾病活動並恢復色素。然而，治療效果有時並不理想，復發頻繁，且達到持續色素恢復仍然具有挑戰性，尤其是在長期或廣泛性病例中。在此背景下，標靶免疫調節療法（包括 JAK 抑制劑和其他標靶訊號路徑的療法）的研發正在加速，促進黑素細胞恢復和色素再生的策略也在不斷探索中。

主要亮點

• 預計到 2026 年，西班牙白斑症患者人數將增加到 2036 年的 206,690 人。
• 白斑症是一種慢性自體免疫皮膚病，其特徵是皮膚色素脫失。
• 皮膚的明顯變化會對患者的生活品質和心理健康產生重大影響。
• 目前，有效且永續的色素再生療法仍存在巨大的未滿足需求。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Minghui Pharmaceutical（Hangzhou）Ltd
• Pfizer
• AbbVie
• Jiangsu HengRui Medicine Co., Ltd.
• Genrix（Shanghai）Biopharmaceutical Co., Ltd.
• Incyte Corporation
• Forte Biosciences, Inc.
• CAGE Bio Inc.
• Clinuvel, Inc.
• InventisBio Co., Ltd.
• Eli Lilly and Company

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖的觀點。
• 值得關注的早期管道

第6章：未滿足的需求與TPP分析

• 新興療法的關鍵未滿足需求和未來成就前景
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Vitiligo Market Outlook and Forecast

Thelansis's "Vitiligo Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vitiligo treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Vitiligo Overview

Vitiligo is a chronic autoimmune skin disorder in which immune-mediated destruction and dysfunction of melanocytes cause well-demarcated areas of depigmentation. The condition can affect any skin site and may involve the hair, mucosal surfaces, and other pigment-bearing tissues. Its course is variable, ranging from stable localized disease to periods of active spread, and spontaneous repigmentation can occur in some patients. Beyond its visible manifestations, vitiligo can substantially affect quality of life, contributing to psychosocial distress, stigma, and reduced confidence. Treatment aims to control disease activity and restore pigmentation through topical corticosteroids, topical calcineurin inhibitors, phototherapy, and, in selected patients, surgical approaches. However, responses can be incomplete, relapse is common, and achieving durable repigmentation remains challenging, particularly in longstanding or extensive disease. These limitations have accelerated development of targeted immunomodulatory therapies, including JAK inhibitors and other pathway-directed approaches, alongside strategies designed to enhance melanocyte recovery and repigmentation.

Key Highlights

• In Spain, the prevalent Vitiligo population is projected to increase from 197,576 in 2026 to 206,690 by 2036.
• Vitiligo is a chronic autoimmune skin disorder characterized by loss of skin pigmentation.
• Visible skin changes can significantly affect patients' quality of life and psychosocial well-being.
• Significant unmet need remains for effective and durable repigmentation therapies.

Market Overview

• The France Vitiligo market is projected to grow from $110M in 2026 to $275M by 2036.
• Market growth is driven by:
• Increasing adoption of targeted therapies, including topical and systemic treatments
• Growing disease awareness and diagnosis
• Future growth will depend on therapies providing durable repigmentation and sustained disease control.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Minghui Pharmaceutical (Hangzhou) Ltd
• Pfizer
• AbbVie
• Jiangsu HengRui Medicine Co., Ltd.
• Genrix (Shanghai) Biopharmaceutical Co., Ltd.
• Incyte Corporation
• Forte Biosciences, Inc.
• CAGE Bio Inc.
• Clinuvel, Inc.
• InventisBio Co., Ltd.
• Eli Lilly and Company

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)